Rare Disease Therapeutics Market 2025-2033 | Market Growth
The Rare Disease Therapeutics Market is projected for significant growth between 2025 and 2033, driven by strategic initiatives from key players, technological advancements, and evolving demand patterns. Valued at US$ 135.88 billion in 2023, it is expected to reach US$ 495.27 billion by 2033 with a CAGR of 13.8%. Recent developments include major acquisitions, expanded clinical programs, and advancements in gene and RNA-based therapies by leading pharmaceutical companies.
APR 1·Business Wire→
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics, Inc. announced that it granted equity awards consisting of 113,855 restricted stock units (RSUs) to 24 new employees hired in the first quarter of 2026. These awards were approved by the Compensation Committee and are considered a material inducement to employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with one-fourth vesting each year, contingent on continued employment.
MAR 26·GuruFocus→
SRPT: Citigroup Raises Price Target Amid Maintained 'Sell' Ratin
Citigroup has maintained its 'Sell' rating on Sarepta Therapeutics (SRPT) while significantly increasing its price target from USD 9.00 to USD 13.00, a 44.44% boost. This adjustment reflects changing market conditions and expectations for SRPT, despite other analysts having "Outperform" or "Overweight" ratings with higher price targets. The average target price from 25 analysts is $30.24, implying a potential upside of 37.95% from the current price, with a "Hold" consensus from 26 brokerage firms.
